A theoretical approach for T-lymphocyte monitoring of autologous cancer vaccine therapy using autologous HLA-class I and HLA-class II constructs.
Schiltz
Patric
P
Patty and George Hoag Cancer Center, Cell Biology Laboratory, Newport Beach, CA 92658, USA. PSchiltz@hoaghospital.org
Dillman
Robert
R
D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000502:physiology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II